APA (7th ed.) Citation

Ghosh Laskar, M., Eriksson, M., Rudling, M., & Angelin, B. (2017). Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C‐III. Journal of internal medicine, 281(6), 575-585. https://doi.org/10.1111/joim.12594

Chicago Style (17th ed.) Citation

Ghosh Laskar, M., M. Eriksson, M. Rudling, and B. Angelin. "Treatment with the Natural FXR Agonist Chenodeoxycholic Acid Reduces Clearance of Plasma LDL Whilst Decreasing Circulating PCSK9, Lipoprotein(a) and Apolipoprotein C‐III." Journal of Internal Medicine 281, no. 6 (2017): 575-585. https://doi.org/10.1111/joim.12594.

MLA (9th ed.) Citation

Ghosh Laskar, M., et al. "Treatment with the Natural FXR Agonist Chenodeoxycholic Acid Reduces Clearance of Plasma LDL Whilst Decreasing Circulating PCSK9, Lipoprotein(a) and Apolipoprotein C‐III." Journal of Internal Medicine, vol. 281, no. 6, 2017, pp. 575-585, https://doi.org/10.1111/joim.12594.